相关临床试验
0
0 进行中
药物批准
2
批准总数
监管机构
1
监管机构数
成立时间
N/A
暂无试验阶段数据
暂无试验数据
暂无试验数据
- Vera Therapeutics reported that Trutakna met all prespecified endpoints in the final ORIGIN 3 analysis of 428 adults with primary IgA nephropathy at risk of progression. - Annualized eGFR slope through 104 weeks was -0.6 mL/min/1.73m2/year with Trutakna versus -5.6 with placebo, a 5.0 mL/min/1.73m2/year treatment effect (p<0.0001). - Composite kidney disease progression events occurred in 11 Trutakna patients versus 38 on placebo, a 76% risk reduction (hazard ratio 0.24; 95% CI 0.12, 0.48). - Vera plans to submit a supplemental BLA in Q4 2026 for full approval, with more than 350 patient start forms generated in the first ten weeks of launch.
- Ligand Pharmaceuticals reported second-quarter 2026 royalty revenue of $48 million, a 32% year-over-year increase driven by Filspari, Ohtuvayre, and Zelsuvmi. - The company completed its $700 million zero-coupon convertible debt financing and closed the XOMA Royalty acquisition, adding more than 120 assets to its portfolio. - Full-year 2026 adjusted EPS guidance was raised at the low end to $9.00 (range: $9.00–$9.50), with royalty revenue guidance reaffirmed at $225–$250 million. - Key pipeline catalysts include Filspari's FSGS approval, Capvaxive's pediatric label expansion, and upcoming pivotal readouts across seven programs over the next 18 months.
- The Alport syndrome market across the 7MM was valued at USD 27 million in 2025, with the United States accounting for approximately 88% of the total market share. - No therapies are currently approved specifically for Alport syndrome; standard care relies on ACE inhibitors, ARBs, and kidney transplantation for end-stage disease. - ENYO Pharma's vonafexor demonstrated positive Phase II ALPESTRIA-1 results in January 2026, showing slowed kidney function decline, with a Phase III trial planned for 2H 2026. - The pipeline includes diverse mechanisms such as ELX-02 for nonsense mutations, setanaxib (NOX1/4 inhibitor), and BAY3401016 (anti-Sema3A monoclonal antibody), with total prevalent cases estimated at ~203,800 in the 7MM in 2025.
- The biotech M&A market is heating up as pharmaceutical companies face a patent cliff that will eliminate $200-250 billion in branded medicine sales by 2032, driving acquisition activity. - Research projects both the number of acquisitions and total dollars spent on deals will increase 15% in 2026, with approximately 520 transactions totaling $230 billion expected across the sector. - Big Pharma is targeting companies with drugs in advanced clinical trials, with 80% of expected 2026 deals focused on acquiring treatments already proven effective in patients. - Key therapeutic areas drawing acquisition interest include diabetes, kidney disease, obesity, radiopharmacy, RNA-based therapies, and cardiovascular diseases.
- Travere Therapeutics achieved record quarterly performance with FILSPARI generating approximately $103 million in net sales and 908 new patient starts in Q4 2025. - The company awaits FDA approval decision for FILSPARI in FSGS by January 13, 2026, which would mark the first approved medication for this rare kidney disorder. - Travere plans to restart its pivotal Phase 3 HARMONY study of pegtibatinase for classical homocystinuria in Q1 2026 following manufacturing optimization.
- Sparsentan achieved a 39.5% reduction in urine protein-to-creatinine ratio at 108 weeks compared to 24.9% with irbesartan in pediatric FSGS patients. - Complete proteinuria remission was achieved by 12.5% of sparsentan-treated patients versus 5.3% with irbesartan, while partial remission occurred in 56.3% versus 36.8% respectively. - The dual endothelin-angiotensin receptor antagonist demonstrated a favorable safety profile with no treatment discontinuations due to adverse events. - FDA approval decision for FSGS indication is expected in January 2026, potentially making sparsentan the first approved agent for this condition.
- Chugai Pharmaceutical will pay 15 billion yen ($98 million) to acquire Tokyo-based Renalys Pharma, gaining partial rights to sparsentan for IgA nephropathy treatment. - The deal includes potential additional payments of 16 billion yen if Renalys' Phase 3 IgA nephropathy trial in Japan yields positive results and regulatory approvals. - Sparsentan is already marketed by Travere Therapeutics as Filspari in the U.S. and Europe for treating the kidney disease IgA nephropathy. - Renalys expects results from its ongoing Phase 3 IgA nephropathy trial in Japan during the fourth quarter of this year.
- Renalys Pharma has completed primary endpoint data collection for its Phase III clinical trial of sparsentan (RE-021) for IgA nephropathy in Japan, measuring urine protein creatinine ratio at 36 weeks. - The company will analyze efficacy and safety data through 36 weeks and compare results with global Phase III trials to prepare for New Drug Application submission. - Sparsentan is an oral dual endothelin and angiotensin II receptor antagonist that received full FDA approval in 2024 for slowing kidney function decline in adults with primary IgA nephropathy. - IgA nephropathy represents a significant unmet medical need in Japan, being designated as an intractable disease and one of the main causes of kidney failure.
- A comprehensive pipeline analysis reveals 12+ companies developing 15+ novel therapies for focal segmental glomerulosclerosis (FSGS), a rare kidney disorder with limited treatment options. - Travere Therapeutics' sparsentan (Filspari) has received FDA acceptance for supplemental approval following successful DUPLEX trial results showing sustained proteinuria reduction in FSGS patients. - Survey data from 102 U.S. nephrologists indicates only half of FSGS patients are considered optimally managed, driving strong physician interest in emerging therapies targeting APOL1-mediated disease. - The next 12-18 months are expected to redefine FSGS treatment standards, with multiple agents advancing toward regulatory milestones and potential FDA decisions in early 2026.
- The FDA has accepted Travere Therapeutics' supplemental New Drug Application for traditional approval of sparsentan (Filspari) in focal segmental glomerulosclerosis, with a decision expected by January 2026. - An FDA advisory committee meeting will be convened to review the application data, signaling the regulatory importance of this potential treatment option for FSGS patients. - If approved, sparsentan would strengthen treatment options for FSGS, a rare kidney disorder with limited therapeutic alternatives and significant unmet medical needs.
